Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02935790
Title Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Acetylon Pharmaceuticals Incorporated
Indications

melanoma

Therapies

Citarinostat + Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
NYU Langone Medical Center New York New York 10016 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field